Therapeutic antibodies in Menarini' Pipeline

Monica Binaschi, Menarini Ricerche

Le nuove sfide della ricerca oncologica: verso una partnership tra Enti Pubblici e Industria nella regione Lazio

May 17, 2017

MENARINI RICERCHE

Menarini Pipeline in Oncology

	Compound	MoA	B/S	Leading Indication	Discovery	Preclinics	PhI	PhII	PhIII
OXFORD BioTherapeutics	MEN1112	ADCC	Biological	AML					
OXFORD BioTherapeutics	MEN1309	ADC	Biological	SOLID TUMORS					
				LYMPHOMA					
CHUGAI	MEN1611	PI3K Inh	Small Molecule	SOLID TUMORS					
Selvita	MEN1703	FLT3/Pim Inh	Small Molecule	AML					

MENARINI RICERCHE

MEN1112

MENARINI
RICERCHE

MEN1112 : de-fucosilated antibody against Bst1/CD157



MENARINI RICERCHE

MEN1112: Mechanism of action

- Very slow internalization of the antigen from cell surface and antibody de-fucosylation
  - IMPROVED ADCC



MENARINI RICERCHE

Translational research: collaboration with research centers

- in AML since:
  - Expression in blasts from AML patients in PB and BM
  - Expression in blasts at the diagnosis and at relapse
  - Expression higher in monocytic blasts
  - Potentially efficacy demonstrated ex-vivo in blasts from AML patients at clinically relevant doses

Institute of Translational Pharmacology, C.N.R., Rome, Italy

G. Sconocchia

Consiglio Nazionale delle Ricerche

Hematology, Department of Biomedicine and Department of Systems Medicine Prevention, University Tor Vergata, Rome, Italy

A. Venditti
F. Buccisano
P. Palomba
S. Amadori

MENARINI RICERCHE

MEN1112: First in Human study

MENARINI
RICERCHE

MEN1309

MENARINI
RICERCHE

MEN1309: ADC against CD205

MEN1309 is a new **ADC** monoclonal antibody conjugated to a toxin…

…which acts as an intelligent weapon instructed to selectively deliver a potent payload to kill cancer cells



MENARINI RICERCHE

Translational Research: de-risking of MEN1309 development

- Prevalence of the antigen in different tumor types- fully annotated samples

- Models of clinical efficacy – PDXs

MENARINI RICERCHE

Translational Research: antitumor activity of MEN1309 in PDX model





Val D'Hebron Institute of Oncology
J Arribas

IOR
F Bertoni

Thank you

MENARINI
RICERCHE